{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor%2C+Primitive&page=2", "query": { "condition": "Neuroectodermal Tumor, Primitive", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor%2C+Primitive&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T20:26:09.617Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02650648", "title": "Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "High-Risk" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "NK cells", "type": "BIOLOGICAL" }, { "name": "hu3F8", "type": "BIOLOGICAL" }, { "name": "rIL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 85, "start_date": "2016-01-05", "completion_date": "2025-07-28", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650648" }, { "nct_id": "NCT04753658", "title": "Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "lorlatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": 15, "start_date": "2021-03-19", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753658" }, { "nct_id": "NCT00730444", "title": "Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Iobenguane I 123 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-11-09", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00730444" }, { "nct_id": "NCT02194452", "title": "Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acoustic Schwannoma", "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Meningioma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Choroid Plexus Tumor", "Adult Craniopharyngioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade I Meningioma", "Adult Grade II Meningioma", "Adult Medulloblastoma", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pilocytic Astrocytoma", "Adult Pineal Gland Astrocytoma", "Adult Pineoblastoma", "Adult Pineocytoma", "Adult Subependymal Giant Cell Astrocytoma", "Adult Subependymoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Supratentorial Ependymoma", "Meningeal Melanocytoma", "Newly Diagnosed Childhood Ependymoma", "Recurrent Adult Brain Tumor", "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Anaplastic Oligoastrocytoma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Diffuse Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Fibrillary Astrocytoma", "Recurrent Childhood Gemistocytic Astrocytoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliomatosis Cerebri", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Oligoastrocytoma", "Recurrent Childhood Oligodendroglioma", "Recurrent Childhood Pilocytic Astrocytoma", "Recurrent Childhood Pilomyxoid Astrocytoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Pleomorphic Xanthoastrocytoma", "Recurrent Childhood Protoplasmic Astrocytoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Untreated Childhood Anaplastic Astrocytoma", "Untreated Childhood Anaplastic Oligodendroglioma", "Untreated Childhood Brain Stem Glioma", "Untreated Childhood Cerebellar Astrocytoma", "Untreated Childhood Cerebral Astrocytoma", "Untreated Childhood Diffuse Astrocytoma", "Untreated Childhood Fibrillary Astrocytoma", "Untreated Childhood Gemistocytic Astrocytoma", "Untreated Childhood Giant Cell Glioblastoma", "Untreated Childhood Glioblastoma", "Untreated Childhood Gliomatosis Cerebri", "Untreated Childhood Gliosarcoma", "Untreated Childhood Medulloblastoma", "Untreated Childhood Oligoastrocytoma", "Untreated Childhood Oligodendroglioma", "Untreated Childhood Pilocytic Astrocytoma", "Untreated Childhood Pilomyxoid Astrocytoma", "Untreated Childhood Pineoblastoma", "Untreated Childhood Pleomorphic Xanthoastrocytoma", "Untreated Childhood Protoplasmic Astrocytoma", "Untreated Childhood Subependymal Giant Cell Astrocytoma", "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor", "Untreated Childhood Visual Pathway and Hypothalamic Glioma", "Untreated Childhood Visual Pathway Glioma" ], "interventions": [ { "name": "gallium Ga 68-edotreotide", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "6 Months to 29 Years" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194452" }, { "nct_id": "NCT00001335", "title": "New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ewing's Sarcoma", "Neuroblastoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "ADR-529", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 90, "start_date": "1993-04", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001335" }, { "nct_id": "NCT06995872", "title": "Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Dinituximab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "3 Years to 35 Years" }, "enrollment_count": 40, "start_date": "2025-10-21", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995872" }, { "nct_id": "NCT06625190", "title": "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Synovial Sarcoma", "Peripheral Nerve Sheath Tumors", "Clear Cell Sarcoma", "Alveolar Soft Part Sarcoma", "Desmoplastic Small Round Cell Tumor", "Chordoma", "Rhabdoid Tumor", "Epithelioid Sarcoma", "Myoepithelial Tumor", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Miltenyi CliniMACS Prodigy ® system", "type": "DEVICE" }, { "name": "Zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 27, "start_date": "2026-02-11", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625190" }, { "nct_id": "NCT01183897", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": null, "sex": "ALL", "summary": "18 Months and older" }, "enrollment_count": 31, "start_date": "2010-08-12", "completion_date": "2018-09-25", "has_results": true, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183897" }, { "nct_id": "NCT00602446", "title": "Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Iron Overload", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer" ], "interventions": [ { "name": "deferasirox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2007-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602446" }, { "nct_id": "NCT00049296", "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-07", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-07-23T20:26:09.617Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049296" } ] }